跳至主要内容
临床试验/NCT04879277
NCT04879277已完成不适用

Etude de l'INflammation systémique de Bas GRade Chez Les Patients Adultes Atteints de PHénylcétonurie

University Hospital, Tours2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年5月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Plasma concentrations of pro-inflammatory cytokines

研究概览

简要总结

Patient suffering from phenylketonuria have chronic hyperphenylalaninemia. Hyperphenylalaninemia is known to be toxic to central nervous system and cardiovascular system in particular through oxydative stress.

In this context, research of low grade systemic inflammation through cytokine assay appears legitimate.

The primary outcome of this study is to describe inflammation profile of patients with phenylketonuria.

详细描述

Phenylketonuria (PKU) is a metabolic hereditary disease due to lack of activity of phenylalanine hydroxylase. This lack of activity whom origin is genetic, results in chronic hyperphenylalaninemia, toxic to central nervous system and cardiovascular system. Without treatment, PKU is responsible for mental retardation in children.

PKU is subject to systematic screening at birth and if diagnosis is confirmed a specific diet controlled in phenylalanine is prescribed for infant. This diet allows a neurodevelopment as closed as healthy infant. Despite this diet, neurological and systemic complications are more often reported at adult age. It is therefore recommended to follow patient regularly in order to search for those complications.

In a PKU murine model, it has been shown (cf references) that a low grade systematic inflammation exists and was reversible after dietetic treatment using glycomacropeptide (through a probiotic effect of this protein naturally phenylalanine free). Existence of this low grade systematic inflammation, evaluated by plasmatic cytokine screening (TNF alpha IL2, IL6, IL10, IFNgamma, IL1Alpha, IL1Beta and protein C reactive) has not been proven in humans to date.

Primary outcome of this study is to characterize this low grade systemic inflammation profile in patient with PKU.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Screening
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Healthy subject

Other

The intervention, specific to the study, is to take blood samples on patients healthy volunteers.

Healthy subject will be paired to patient with phenylketonuria according to body mass index and sex.

干预措施: Blood samples (Biological)

Patient with phenylketonuria

Other

The intervention, specific to the study, is to take blood samples on patients with phenylketonuria

干预措施: Blood samples (Biological)

结局指标

主要结局

Plasma concentrations of pro-inflammatory cytokines

时间窗: At the inclusion

Plasmatic pro-inflammatory cytokine assay in PKU patients and healthy subjects.

Plasma concentrations of CRP

时间窗: At the inclusion

Plasmatic CRP assay in PKU patients and healthy subjects.

次要结局

  • Plasma concentrations of phenylalanine(At the inclusion)
  • Plasma concentrations of tyrosine(At the inclusion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验